New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
13:36 EDTSYK, NVDQ, ISRGIntuitive Surgical rises after Q2 EPS, revenue beat expectations
Shares of surgical instrument and accessory maker Intuitive Surgical (ISRG) are climbing after the company reported second quarter earnings per share and revenue that surpassed analysts' expectations. WHAT'S NEW: Intuitive Surgical's Q2 adjusted EPS was $3.73, while its GAAP EPS $2.77. Analysts' EPS consensus for the quarter was $2.83. The company's Q2 revenue was $512.2M, which was higher than analysts' consensus of $501.7M. Intuitive Surgical said it ended the quarter with $2B in cash, cash equivalents, and investments, which is a decrease of $920M during the quarter, primarily reflecting the impact of $1B utilized during the quarter to repurchase shares of its common stock. It reported that its Q2 worldwide procedures grew 9% over 2Q13 and said it shipped 96 systems during Q2, compared with 87 systems that were shipped last quarter. WHAT'S NOTABLE: During the company's conference call, Intuitive Surgical narrowed its FY14 procedure growth view to 5%-8% from 2%-8%. The company said said that it expects capital pressures in most hospitals to continue and projects international procedure growth to be "lumpy" quarter-over-quarter. ANALYST REACTION: Raymond James analyst Lawrence Keusch upgraded Intuitive Surgical to Outperform from Market Perform this morning following the company's better than anticipated Q2 earnings results. The analyst, who has a $500 price target on the stock, said that the company's results inferred a stabilization in the business in both its system placements and procedures. For this reason, the firm is taking a more positive view of Intuitive Surgical. Keusche said he now sees 10% top-line growth and 18% EPs growth in 2015-2016. Stifel analyst Rick Wise upgraded Intuitive Surgical to Buy from Hold with a $600 price target with the belief that the company's longer-term growth reacceleration drivers are slowly falling into place. Wise feels that procedure volumes for the company look to be recovering, new products launches are going well and future product reveals are set to occur. The firm feels that the risk of 2H14 downward estimate revisions are definitely lower than in prior quarters. Meanwhile, Leerink analyst Richard Newitter remains cautious on Intuitive Surgical's results. He feels that the quarter was encouraging for Intuitive Surgical, but that it is difficult to be confident that a sequential increase in procedure growth could mark a definitive point of emphasis. The firm increased its price target to $450 from $415 based on its higher estimate revisions to its adjusted GAAP EPS view. PRICE ACTION: During afternoon trading, shares of Intuitive Surgical rose $57.76 or 14.73%, to $449.92. OTHERS TO WATCH: Novadaq (NVDQ), which sells consoles for Intuitive Surgical's robotic systems, fell 2c to $16.68. Shares of Stryker (SYK), which previously acquired robotic surgery systems maker MAKO Surgical, were up slightly by 10c to $81.99.
News For ISRG;NVDQ;SYK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 22, 2015
16:58 EDTISRGIntuitive Surgical sees FY15 gross profit margin similar to Q4
Subscribe for More Information
16:57 EDTISRGIntuitive Surgical sees 2015 procedural growth 7%-10%
Subscribe for More Information
16:54 EDTISRGIntuitive Surgical encouraged by clinical developments in Europe
Subscribe for More Information
16:51 EDTISRGIntuitive Surgical says Q4 U.S procedures grew 8%, international grew 21%
Subscribe for More Information
16:39 EDTISRGIntuitive Surgical received regulatory clearance for da Vinci Xi system in Korea
Subscribe for More Information
16:07 EDTISRGIntuitive Surgical Q4 worldwide da Vinci procedures grew nearly 10% YoY
The company placed 137 da Vinci Surgical Systems, compared to 138 in the fourth quarter of 2013 and 111 in the third quarter of 2014.
16:06 EDTISRGIntuitive Surgical reports Q4 EPS $4.92, consensus $4.38
Reports Q4 non-GAAP revenue $601M, consensus $589.37M.
15:32 EDTISRGNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Starbucks (SBUX), consensus 80c; Capital One (COF), consensus $1.74; Intuitive Surgical (ISRG), consensus $4.38; KLA-Tencor (KLAC), consensus 52c; Altera (ALTR), consensus 35c; E-Trade (ETFC), consensus 23c... ResMed (RMD), consensus 62c; Maxim Integrated Products (MXIM), consensus 30c; Maxim Integrated Products (MSCC), consensus 65c; Hexcel (HXL), consensus 54c; Polycom (PLCM), consensus 23c; Skyworks (SWKS), consensus $1.19; Curtiss-Wright (CW), consensus $1.00.
15:05 EDTISRGIntuitive Surgical January weekly 525 straddle priced for 5.4% movement into Q4
12:52 EDTISRGEarnings Preview: Intuitive Surgical sees Q4 da Vinci sales up 5% on GAAP basis
Subscribe for More Information
12:10 EDTISRGIntuitive Surgical technical comments before results
The shares have been in a consolidation phase for the last month ahead of results. The low of the recent range is at $513 and the high of the range is at $538. Breaks of either end of this range will likely determine the future price path of the shares. A breakout above $538 on positive news would likely also tick the 52-week high at $541.23. Resistance levels to watch thereafter would be at $550, $567, and $574. A breakdown below the low of the range on a negative surprise would be bearish for future price. Below $513 next supports would be at $496.66, $486.61, and $467.26. The stock does have a history of extreme price reactions around earnings exacerbated by the small trading float. As of the last available report, the short-base in the name was neutral and relatively low compared to prior history.
January 21, 2015
08:40 EDTISRGIntuitive Surgical January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
January 15, 2015
10:19 EDTISRGOptions with decreasing implied volatility
Subscribe for More Information
January 14, 2015
10:10 EDTSYKHigh option volume stocks
Subscribe for More Information
January 13, 2015
17:43 EDTSYKStryker sees FY15 EPS negatively impacted by 20c
Subscribe for More Information
17:40 EDTSYKStryker sees FY14 EPS $4.72-$4.74, consensus $4.75
Sees FY14 revenue $9.7B, consensus $9.69B.
17:39 EDTSYKStryker sees Q4 adjusted EPS $1.43-$1.45, consensus $1.46
Subscribe for More Information
08:57 EDTNVDQNovadaq shares should be bought on weakness, says JMP Securities
Subscribe for More Information
08:40 EDTISRGIntuitive Surgical reports preliminary Q4 revenue $605M, consensus $587.48M
Intuitive Surgical announced certain unaudited preliminary Q4 financial results. The company expects GAAP revenue for Q4 of approximately $605M, up approximately 5% from $576M for the 4Q13. The company expects non-GAAP revenue for Q4 of approximately $601M, which excludes approximately $4M of revenue associated with da Vinci Xi trade-out offers. The unaudited preliminary results are prior to the completion of our annual independent audit and therefore are subject to adjustment. Preliminary Q4 instruments and accessories revenue on a GAAP basis is expected to increase approximately 5% to approximately $281M from $268M during 4Q13. Preliminary fourth quarter 2014 da Vinci Surgical Systems revenue on a GAAP basis is expected to increase approximately 5% to approximately $214M from $205M during 4Q13. The company placed 137 da Vinci Surgical Systems during Q4, compared with 138 systems during 4Q13. The Preliminary Q4 GAAP service revenue is expected to increase approximately 6% to approximately $110M from $103M during 4Q13.
07:42 EDTNVDQJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use